Oskar Lund

Oskar Lund joined the company in 2021 at a pivotal stage in the Company's development as it eyes a potential IPO following recent positive results from the first in human (FIH) trial of its lead candidate ILP100 and approved phase II programs. Provious appointments include Disruptive Materials (DM), having engineered the strategic split of the company into two groups along with a successful c-round funding of the newly spun-out pharma business. This is backed by a strong track record of successful fund raising combined with in-depth financial management and strategic business development experience in the private, corporate and public sectors, including GE, BNP Paribas and JP Morgan.

Photo from DM.

Till personlistan